For the quarter ending 2025-09-30, DAWN had $7,655K increase in cash & cash equivalents over the period. -$5,805K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -19,726 | -66,318 |
| Acquired in-process research and development asset | 0 | - |
| Share-based compensation expense | 9,561 | 23,759 |
| Depreciation expense | 90 | 185 |
| Accretion of discounts on short-term investments, net | 4,121 | 8,402 |
| Amortization of intangible assets | 795 | 1,520 |
| Amortization of operating right-of-use asset | 49 | 153 |
| Loss from sale of property and equipment | 0 | -71 |
| Gain from sale of priority review voucher | 0 | 0 |
| Accounts receivable, net | -2,972 | 5,793 |
| Inventory | 480 | 3,152 |
| Prepaid expenses and other current assets | -480 | 1,707 |
| Deposits and other long-term assets | 134 | 62 |
| Accounts payable | 688 | 1,828 |
| Accrued expenses and other current liabilities | 4,079 | -26,494 |
| Deferred revenue | 52 | 431 |
| Operating lease liability | -110 | 178 |
| Net cash used in operating activities | -5,805 | -83,803 |
| Cash paid for purchase of short-term investments | 209,565 | 428,298 |
| Proceeds from maturity of short-term investments | 648,820 | - |
| Proceeds from sale of short-term investments | -425,795 | 425,795 |
| Cash paid for acquired intangible assets | 0 | 3,500 |
| Proceeds from sale of priority review voucher | 0 | 0 |
| Cash paid for acquiredin-processresearch and development assets | 0 | - |
| Cash paid for purchase of property and equipment | 0 | 320 |
| Proceeds from sale of property and equipment | 0 | 32 |
| Net cash provided by investing activities | 13,460 | -6,291 |
| Proceeds from issuance of common stock in connection with private placement, net of placement agent fees and offering costs | 0 | - |
| Proceeds from issuance of prefunded warrants to purchase common stock, net of issuance costs | 0 | - |
| Proceeds from issuance of common stock upon stock option exercises | 0 | 0 |
| Proceeds from issuance of common stock upon employee stock purchase plan purchase | 0 | 748 |
| Cash provided by financing activities | 0 | 748 |
| Net (decrease) increase in cash and cash equivalents | 7,655 | -89,346 |
| Cash and cash equivalents at beginning of period | 124,968 | - |
| Cash and cash equivalents at end of period | 43,277 | - |
Day One Biopharmaceuticals, Inc. (DAWN)
Day One Biopharmaceuticals, Inc. (DAWN)